Chase Weizer

Background

About Chase Weizer

I am an aspiring physician-scientist and rising young professional in the field of clinical, translational biomedical hematology and oncology research. During my undergraduate experience, I majored in biochemistry and molecular biology and engaged in research centered around targeting expression of putative genes of interest in order to genetically reprogram acute myeloid leukemia (AML) cells to self-destruct. My undergraduate laboratory experience included bacterial transformation, plasmid isolation, transfection via electroporation, RNA isolation, cDNA synthesis, Western blot, and real time-quantitative polymerase chain reaction (RT-qPCR). My colleagues would describe me as a driven, resourceful individual who resiliently completes any impending task, even in the face of adversity. I am a hardworking and motivated individual, dedicated to further expanding my knowledge of hematologic and oncologic disorders, the oncogenic signaling pathways that regulate them, and the development of novel therapeutics to advance clinical outcomes. Currently, I work as a research technician at the Dana-Farber Cancer Institute in the Murakami laboratory studying identify targetable biological vulnerabilities in primary human B-cell acute lymphoblastic leukemia (B-ALL) and various B-cell lymphomas in order to elucidate novel therapeutics suitable for testing in preclinical models and early phase clinical trials. My current scientific focus includes the clinical investigation of novel, multi-arm chemotherapy regimens in the newly diagnosed, pretreatment and relapsed/refractory settings of B-ALL, targeting glycoproteomic interactions within the bone marrow vascular niche to modulate drug-tolerant persister cells, and profiling the chromatin accessibility landscape associated with malignant B-cell differentiation to better characterize malignant developmental clones and identify rare progenitors for therapeutic targeting.